FHTX Foghorn Therapeutics Inc

USD 6.71 0.43 6.847134
Icon

Foghorn Therapeutics Inc (FHTX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 6.71

+0.43 (+6.85)%

USD 0.28B

0.07M

USD 9.50(+41.58%)

USD 6.00 (-10.58%)

Icon

FHTX

Foghorn Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 6.71
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.28B

USD 6.00 (-10.58%)

USD 6.71

Foghorn Therapeutics Inc (FHTX) Stock Forecast

Show ratings and price targets of :
USD 9.50
(+41.58%)

Based on the Foghorn Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Foghorn Therapeutics Inc is USD 9.50 over the next 12 months. Foghorn Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Foghorn Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Foghorn Therapeutics Inc’s stock price was USD 6.71. Foghorn Therapeutics Inc’s stock price has changed by +2.13% over the past week, -13.75% over the past month and +17.51% over the last year.

No recent analyst target price found for Foghorn Therapeutics Inc
No recent average analyst rating found for Foghorn Therapeutics Inc

Company Overview Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Co...Read More

https://foghorntx.com

500 Technology Square, Cambridge, MA, United States, 02139

0

December

USD

USA

Adjusted Closing Price for Foghorn Therapeutics Inc (FHTX)

Loading...

Unadjusted Closing Price for Foghorn Therapeutics Inc (FHTX)

Loading...

Share Trading Volume for Foghorn Therapeutics Inc Shares

Loading...

Compare Performance of Foghorn Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for FHTX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Foghorn Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing FHTX

Symbol Name FHTX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Foghorn Therapeutics Inc (FHTX) Stock

Based on ratings from 2 analysts Foghorn Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on FHTX's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for FHTX is USD 9.50 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on FHTX's stock to indicate if its overvalued.

The last closing price of FHTX's stock was USD 6.71.

The most recent market capitalization for FHTX is USD 0.28B.

Based on targets from 2 analysts, the average taret price for FHTX is projected at USD 9.50 over the next 12 months. This means that FHTX's stock price may go up by +41.58% over the next 12 months.

We can't find any ETFs which contains Foghorn Therapeutics Inc's stock.

As per our most recent records Foghorn Therapeutics Inc has 0 Employees.

Foghorn Therapeutics Inc's registered address is 500 Technology Square, Cambridge, MA, United States, 02139. You can get more information about it from Foghorn Therapeutics Inc's website at https://foghorntx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...